Anavex Life Sciences (AVXL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Anavex Life Sciences (AVXL) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.07 of bullish evidence against -0.37 bearish.

Anavex Life Sciences last closed at $1.49, -3.25% on the session.

Against the IVW growth benchmark the position is -4.05% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for AVXL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Anavex Life Sciences in the 31st percentile on return on equity, where 100 is best.

Anavex Life Sciences is classified under Health Care / Biotechnology, with a market capitalisation of $142.75M.

StockMap tracks Anavex Life Sciences as the 267th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Anavex Life Sciences ranks 319th of 381 in the group, against a group median of -0.08.